2016 Hematological Malignancies

Diagnosis:

• A CT-guided percutaneous biopsy: DLBCL. – sheets of malignant large lymphocytes which were CD79a+, CD20+ confirming B-cell origin. – Further immunohistochemistry confirmed activated B-cell subtype of DLBCL, which is MUM1+, BCL2+, BCL6+, p53+, CD30+/-, CD10+/- – proliferation fraction (Ki67) > 90%. – In situ hybridization showed no MYC, IgH, BCL2, or BCL6 rearrangements.